VISIT BRILINTATOUCHPOINTS.COM
• Premature discontinuation increases the risk of MI,
stent thrombosis, and death
• Dyspnea was reported in 14% of patients treated with
BRILINTA and in 8% of patients taking clopidogrel.
Dyspnea resulting from BRILINTA is self-limiting. Rule
out other causes
• BRILINTA is metabolized by CYP3A4/5. Avoid use with
strong CYP3A inhibitors and potent CYP3A inducers.
Avoid simvastatin and lovastatin doses >40 mg
• Monitor digoxin levels with initiation of, or any change in,
BRILINTA therapy
ADVERSE REACTIONS
• The most com